Voting Rights and Capital

Date: 2 March 2010

Vernalis plc ("the Company")

Voting Rights and Capital

In accordance with DTR 5.6:

Following the Placing and Open Offer and the Share Capital Reorganisation, whereby shares have been subdivided to reduce the nominal value of each Ordinary Share to 1 pence, the Company's New Ordinary Shares were admitted to trading on the London Stock Exchange and to listing on the Official List of the Financial Services Authority earlier today. The Company's issued share capital as at 2 March 2010 consists of 99,571,509 Ordinary Shares of 1 pence each with voting rights. No shares are held in treasury. Therefore, the total number of voting rights in the Company is 99,571,509.

The above figure (99,571,509) may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the FSA's Disclosure and Transparency Rules.

Please note that the ISIN for Vernalis plc (LSE: VER) Ordinary Shares has not changed from GB00B3Y5L754.

About Vernalis:

Vernalis is a development stage pharmaceutical company with significant expertise both in de novo fragment and structure-based drug discovery and pre-clinical and clinical development. The Group has five priority product candidates in clinical development (three of which are partnered), two further priority programmes in pre-clinical development (neither of which is partnered) and other collaborative drug discovery programmes. Vernalis has a further two partnered programmes that are in clinical development in which it retains an economic interest. Our technologies, capabilities and products are endorsed by collaborations with leading, global pharmaceutical companies including GSK, Biogen Idec, Novartis, Servier, Chiesi, Menarini, and Endo.

For further information about Vernalis, please visit www.vernalis.com.